Share Twitter LinkedIn Facebook Email Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses Data On The ALLIANCE Trial. At MOASC on Jan 19, 2019.
ASH 2025 Lymphoma Highlights: Epcoritamab, S1826, Mosunetuzumab & ctDNA | Dr. Sworder ASH 6 Mins Read
2025 Leukemia / Lymphoma Updates with Aaron Goodman, MD – UC San Diego – MOASC Hematologic Malignancies 6 Mins Read
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read
